REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form
Back to Research Library

FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form

The U.S. Food and Drug Administration (FDA) has proposed a significant change that could impact how certain peptide drugs are distributed and used within the healthcare system. The agency is considering excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances allowed under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). This move could limit how these drugs are compounded in outsourcing facilities, affecting their availability for patients.

Background

Peptide drugs like semaglutide, tirzepatide, and liraglutide have become increasingly popular due to their effectiveness in treating conditions such as type 2 diabetes and obesity. These medications work by mimicking or enhancing the action of naturally occurring peptides in the body. The FDA’s decision to potentially exclude these drugs from the list of bulk substances that can be compounded is based on a lack of clinical evidence suggesting a need for them to be produced this way.

Outsourcing facilities play a crucial role in compounding medications, which involves mixing or assembling ingredients under sterile conditions to create personalized medications. The 503B bulks list includes approved active pharmaceutical ingredients (APIs) that these facilities can use to compound drugs. If the FDA’s proposal is finalized, outsourcing facilities would no longer be able to use bulk forms of semaglutide, tirzepatide, and liraglutide to create compounded medications.

Key Details

The proposed exclusion was announced in a recent press release from the FDA on April 30, 2026. The agency stated that there is no clinical need for these specific peptide drugs to be produced through compounding processes using bulk substances. This means that patients would likely have to rely solely on commercially manufactured versions of semaglutide, tirzepatide, and liraglutide.

The move by the FDA reflects a broader trend towards ensuring patient safety and quality control in pharmaceutical manufacturing. By restricting the use of these peptide drugs in compounded forms, the agency aims to prevent potential risks associated with improper compounding practices. However, this decision could also affect access to customized or tailored versions of these medications that some patients might need.

Key Takeaways

  • Clinical Need: The FDA determined there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk substances.
  • Safety Considerations: This proposal aims to enhance patient safety by reducing the risk of improper compounding practices with these peptides.
  • Regulatory Changes: The decision could lead to changes in how these medications are distributed and used, impacting both healthcare providers and patients.
  • Patient Impact: Patients may need to rely more heavily on commercially manufactured versions of these drugs.

What This Means

For the peptide research community and clinicians working with these medications, this proposed change highlights the ongoing importance of FDA regulation in ensuring patient safety. While it could limit some compounding practices, it also underscores the agency’s commitment to maintaining high standards for pharmaceutical products. For patients currently using or considering these drugs, it means that personalized compounded versions might become less available.

The proposal is open for public comment and review, which provides an opportunity for stakeholders to voice their opinions on this significant regulatory change. As the FDA continues to evaluate feedback, the peptide community can expect further guidance and updates from the agency regarding these medications and potential implications for clinical practice.

---

Source: [FDA Press Release](http://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list) — Published 2026-04-30

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.